

Date: October 21, 2024

To,
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block-G
Bandra Kurla Complex
Bandra East
Mumbai 400 051
Maharashtra, India

The General Manager
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 001
Maharashtra, India

Symbol: EPIGRAL

Scrip Code: 543332

Dear Sir/Madam,

Re: **Qualified institutions placement of equity shares of face value of ₹10 each (the “Equity Shares”) by Epigral Limited (formerly known as Meghmani Finechem Limited) under the provisions of Chapter VI of Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (the “SEBI ICDR Regulations”) and Sections 42 and 62 of the Companies Act, 2013 and the rules made thereunder, each as amended (the “Company) (the “Issue”)**

Sub: **Outcome of the meeting of the Fund Raising Committee**

We wish to inform you that pursuant to the approval of the board of directors of the Company at its meeting held on August 14, 2024 and approval of the shareholders of the Company by way of a special resolution passed by way of Postal Ballot on September 16, 2024, the Fund Raising Committee of the Company, in its meeting held today i.e. October 21, 2024, has inter alia considered and approved the following:

- (i) approval and adoption of the preliminary placement document dated October 21, 2024, and the draft of application form, in connection with the Issue (“**Preliminary Placement Document**”);
- (ii) authorizing the opening of the proposed issue of such number of Equity Shares to eligible qualified institutional buyers through a qualified institutions placement under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended (“**SEBI ICDR Regulations**”) and Section 42 of the Companies Act, 2013, read with Rule 14 of the Companies (Prospectus and Allotment of Securities) Rules, 2014, each as amended, today, i.e. on October 21, 2024; and
- (iii) approval of the floor price for the Issue, being ₹2203.29 per Equity Share (“**Floor Price**”) based on the pricing formula as prescribed under Regulation 176 of the SEBI ICDR Regulations.

We further wish to inform you that the Fund Raising Committee has fixed the ‘Relevant Date’ for the purpose of the Issue, in terms of Regulation 171(b)(i) of the SEBI ICDR Regulations as October 21, 2024 and accordingly the floor price in respect of the Issue, based on the pricing formula as prescribed under Regulation 176(1) of the SEBI ICDR Regulations is ₹2203.29 per Equity Share. Pursuant to Regulation 176(1) of the SEBI ICDR Regulations, and in accordance with the approval of the shareholders of the Company accorded through a special resolution passed by way of Postal Ballot on September 16, 2024, the Company may, at its discretion, offer a discount of not more than 5% (five percent) on the Floor Price so calculated for the Issue. The Issue price will be determined by the Company in consultation with the book running lead manager appointed in relation to the Issue. The Fund Raising Committee meeting commenced at 09:00 p.m. and the meeting was concluded at 09:20 p.m.



Epigral Limited

(formerly known as **Meghmani Finechem Limited**)

Epigral Tower, Behind Safal Profitaire, Corporate Road
Prahaldnagar, Ahmedabad 380015, Gujarat, India.

T +91 79 2970 9600

E info@epigral.com

W epigral.com

In relation to the qualified institutions placement, we will file the preliminary placement document with your office today. A copy of the same is also being made available on the website of our Company at www.epigral.com.

Further, as per Company's Code of Conduct for Prevention of Insider Trading and Code of Corporate Disclosure Practices ("Code"), the trading window for dealing in the securities of the Company had already been closed from 1st October, 2024 as intimated vide our letter dated 26th September, 2024 and will remain closed till 48 hours after determination of issue price for all 'Specified Persons' as defined in the Code.

We request you to take the above on record, and the same be treated as compliance under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Thanking you,

Yours faithfully
For Epigral Limited
(formerly known as Meghmani Finechem Limited)

Gaurang Trivedi
Company Secretary and Compliance Officer
Membership No. A22307
Place: Ahmedabad

